CyTOF
Ronald D. Vale is a Professor of Cellular and Molecular Pharmacology at UCSF. His research is focused on molecular motors, particularly on kinesin and dynein. This year he was awarded the Albert Lasker Basic Medical Research Award and the Wiley Prize in Biomedical Sciences. He is a Fellow of the American Academy of Arts and Science and a Member of the National Academy of Science. He has been an Investigator with the Howard Hughes Medical Institute since 1995. Vale is the co-founder of Cytokinetics. He also founded iBioSeminars, which are free online talks by research scientists, and MicroManager, free and open-sourcemicroscopy software.
Craig B. Thompson is the President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center. He currently serves as member of the Medical Advisory Board of the Howard Hughes Medical Institute, a member of the Board of Directors of the American Association for Cancer Research, a member of the Lasker Prize Jury, and Associate Editor of Cell, Immunity, and Cancer Cell. In the past, Dr. Thompson has served as the Chairman of the Scientific Advisory Board of the Damon Runyon/Walter Winchell Cancer Foundation, Chairman of the Board of Scientific Counselors of the National Cancer Institute, and a member of the Experimental Immunology Study Section of the National Institutes of Health. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis, and is a founder of three biotechnology companies. He is an elected member of the National Academy of Sciences, theInstitute of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and the American Association of Physicians. Thompson’s work has elucidated processes that shape lymphocyte development and immune system homeostasis. His current research focuses on the role that metabolic changes play in the origin and progression of cancer.
Raghu Kalluri was Chief of the Division of Matrix Biology and subsequently promoted to Professor of Medicine at Harvard Medical School. In 2012, Dr. Kalluri moved to UT MD Anderson Cancer Center as the Chairman and Professor of Cancer Biology and Director of the Metastasis Research Center. His laboratory is interested in the study of cell and tissue microenvironment and its impact on cancer progression and tissue fibrosis.
David Baltimore is the Robert A. Millikan Professor of Biology at Caltech and discoverer of reverse transcriptase andNF-κB. He shared the 1974 Nobel Prize with Howard Temin and Renato Dulbecco for their discoveries concerning the interaction between tumor viruses and the genetic material of the cell. Baltimore was the founding director of MIT's Whitehead Institute, and he has served as president of Rockefeller University, Caltech, and the American Association for the Advancement of Science. Baltimore is a member of The Jackson Laboratory's Board of Trustees, the Bulletin of the Atomic Scientists' Board of Sponsors, the National Academy of Sciences USA (NAS), the NAS Institute of Medicine (IOM), Amgen, Inc. Board of Directors, the BB Biotech AG Board of Directors, the National Institutes of Health (NIH) AIDS Vaccine Research Committee (AVRC), and numerous other organizations and their boards.
Laurence Zitvogel is the Research Director at Institut National de la Santé et Recherche Médicale. Her expertise is mainly dendritic cell and innate effector biology and relevance during tumor development, as well as exosome-based vaccine designs.
Joan Massagué is Alfred P. Sloan Chair of the Sloan-Kettering Institute’s Cell Biology Program and the founding Chair of the Cancer Biology and Genetics Program. He is also the Director of Memorial Sloan-Kettering’s Metastasis Research Center and a professor at the Weill Cornell Graduate School of Medical Sciences. He is a member of the National Academy of Sciences and a Howard Hughes Medical Institute investigator. Massagué’s past and current research has focused on the study of signaling mechanisms by the cytokine transforming growth factor-β (TGF-β) that are essential for embryonic development, immunity, and maintenance of normal tissues, and whose alterations are a cause of congenital disorders and cancer. His work has been recognized for having implications for the prevention and treatment of cancer metastasis.
Douglas A. Melton is the Xander University Professor at Harvard University and an investigator at the Howard Hughes Medical Institute. He also serves as the co-director of the Harvard Stem Cell Institute and the co-chair of the Harvard University Department of Stem Cell and RegenerativeBiology. He serves on the Scientific Advisory Board of the Genetics Policy Institute, holds membership in the National Academy of the Sciences, and is a founding member of the International Society for Stem Cell Research. His current research interests include pancreatic developmental biology and thedirected differentiation of human embryonic stem cells, and his lab has shown that exocrine cells can be converted to beta cells without reversion to a pluripotent stem cell state. When President George W. Bush cut federal funding of embryonic stem cell research, Melton used private donations to create seventeen stem cell lines and distribute them without charge to researchers around the world. In 2007 and 2009, Melton was listed among Time Magazine's 100 Most Influential People in The World.
